Following the conclusion of a Phase I proof-of-mechanism study of its investigational medicine TAK-062, Takeda has announced its acquisition of PvP Biologics.
TAK-062 is meant to be used for providing the treatment of uncontrolled celiac disease. This is highly potent super glutenase, a protein that degrades ingested gluten that was computationally engineered to treat coeliac disease.
Asit Parikh, head of gastroenterology therapeutic area unit at Takeda, says:
“Many people living with celiac disease manage their symptoms by following a gluten-free diet, but there is no treatment for those who continue to experience severe symptoms. PvP Biologics’ work demonstrated that TAK-062 is a highly targeted therapy that could change the standard of care in celiac disease. We are now applying our deep expertise in gastrointestinal diseases to advance the clinical study of TAK-062 and TAK-101, two programs with different modalities that have both demonstrated clinical proof of mechanism.”
Celiac disease is defined as a genetically driven chronic immune-mediated disorder. In this disease, abnormal immune responses to gluten peptides damage the small intestinal mucosal. The symptoms of Celiac disease include abdominal pain, diarrhoea, nausea, and vomiting.
Pharamaceuticals, PvP Biologics, Takeda